Breakthrough therapy

Results: 60



#Item
21State of Illinois Illinois Department of Public Health Ryan White Part B ADAP Medication Assistance Program (MAP) Application for Pre Approval of Hepatitis C Medication Assistance The following medications are n o w avai

State of Illinois Illinois Department of Public Health Ryan White Part B ADAP Medication Assistance Program (MAP) Application for Pre Approval of Hepatitis C Medication Assistance The following medications are n o w avai

Add to Reading List

Source URL: hivcareconnect.com

Language: English - Date: 2016-05-03 16:46:58
22Reset Form SPECIAL AUTHORIZATION REQUEST ESBRIET® (pirfenidone) Fax requests toOR mail requests to PEI Pharmacare, P.O. Box 2000, Charlottetown, PE, C1A 7N8

Reset Form SPECIAL AUTHORIZATION REQUEST ESBRIET® (pirfenidone) Fax requests toOR mail requests to PEI Pharmacare, P.O. Box 2000, Charlottetown, PE, C1A 7N8

Add to Reading List

Source URL: www.gov.pe.ca

Language: English - Date: 2016-05-27 11:46:42
23Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translatio

Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translatio

Add to Reading List

Source URL: www.pmda.go.jp

Language: English - Date: 2016-08-04 23:27:22
24

PDF Document

Add to Reading List

Source URL: www.hepcoalition.org

Language: English - Date: 2014-09-26 10:10:18
25This is an electronically controlled document. User is responsible to verify and use the current revision. GENERAL CONFORMITY CERTIFICATE Pursuant to 15 U.S.C. § 2063(a), Gilead Sciences, Inc. certifies that based on a

This is an electronically controlled document. User is responsible to verify and use the current revision. GENERAL CONFORMITY CERTIFICATE Pursuant to 15 U.S.C. § 2063(a), Gilead Sciences, Inc. certifies that based on a

Add to Reading List

Source URL: www.gilead.com

Language: English - Date: 2014-07-23 23:05:41
26This is an electronically controlled document. User is responsible to verify and use the current revision. GENERAL CONFORMITY CERTIFICATE Pursuant to 15 U.S.C. § 2063(a), Gilead Sciences, Inc. certifies that based on a

This is an electronically controlled document. User is responsible to verify and use the current revision. GENERAL CONFORMITY CERTIFICATE Pursuant to 15 U.S.C. § 2063(a), Gilead Sciences, Inc. certifies that based on a

Add to Reading List

Source URL: www.gilead.com

Language: English - Date: 2014-07-23 17:05:40
27SPECIAL AUTHORIZATION REQUEST FORM

SPECIAL AUTHORIZATION REQUEST FORM

Add to Reading List

Source URL: www.health.gov.nl.ca

Language: English - Date: 2015-07-10 08:31:24
28SPECIAL AUTHORIZATION REQUEST FORM The Newfoundland and Labrador Prescription Drug Program (NLPDP) Request for Coverage of Harvoni®, Solvadi® and Ibavyr® Pharmaceutical Services Department of Health and Community Serv

SPECIAL AUTHORIZATION REQUEST FORM The Newfoundland and Labrador Prescription Drug Program (NLPDP) Request for Coverage of Harvoni®, Solvadi® and Ibavyr® Pharmaceutical Services Department of Health and Community Serv

Add to Reading List

Source URL: www.health.gov.nl.ca

Language: English - Date: 2015-07-10 08:27:35
29A Breakthrough in Understanding People What Our Auras Reveal About Who We Really Are People spend millions of dollars on therapy and self-help products trying to figure out who they are and how to be happy. If they only

A Breakthrough in Understanding People What Our Auras Reveal About Who We Really Are People spend millions of dollars on therapy and self-help products trying to figure out who they are and how to be happy. If they only

Add to Reading List

Source URL: www.auracolors.com

Language: English - Date: 2015-04-13 11:45:21
    30In renal transplant patients at high-immunologic risk • Rapamune and Cyclosporine Combination Therapy (for the first 12 months post-transplantation): One loading dose of up to 15 mg on day 1, followed by daily mainten

    In renal transplant patients at high-immunologic risk • Rapamune and Cyclosporine Combination Therapy (for the first 12 months post-transplantation): One loading dose of up to 15 mg on day 1, followed by daily mainten

    Add to Reading List

    Source URL: www.accessdata.fda.gov

    Language: English - Date: 2015-05-29 12:30:12